Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 versus guselkumab in moderate to severe Crohn's disease
ISRCTN14103793Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing JNJ-78934804 with Guselkumab (2 arms). Primary endpoints: Clinical remission at week 48 and Endoscopic remission at week 48. Started May 2026; status: recruiting.
02
Drugs
guselkumab + golimumabguselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN14103793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14103793.